Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 12/20 | 0.61 |
| ▸ | CA1 | P00915 | 12/20 | 0.61 |
| ▸ | CA9 | Q16790 | 12/20 | 0.61 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710011 | 0.82 | LOX (0.46) | — | |
| SCHEMBL22558460 | 0.81 | LMNA (0.43) | CA2CA12CA1CA9TSHR | |
| SCHEMBL2262111 | 0.79 | CA1 (0.65) | CA2CA12CA1CA9CA4 | |
| SCHEMBL1306384 | 0.78 | GABRA1 (0.38) | TSHR | |
| SCHEMBL18946201 | 0.78 | LMNA (0.47) | CA2CA12CA1CA9TSHR | |
| SCHEMBL5867219 | 0.78 | CA2 (0.68) | CA2CA12CA1CA9CA4 | |
| SCHEMBL28553405 | 0.77 | CA2 (0.56) | CA2CA1CA9 | |
| SCHEMBL1306505 | 0.76 | APP (0.41) | — | |
| SCHEMBL22243575 | 0.74 | CA12 (0.63) | CA2CA12CA1CA9CA4 | |
| SCHEMBL20610141 | 0.74 | ALDH1A1 (0.49) | CA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3893934-B1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-09-10 | — | — | EP | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20250206798-A1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-06-26 | — | — | US | disclosed |
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325378-A | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | 柯巴斯医药有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-12195510-B2 | Insulin conjugates | SANOFI (FR) | 2025-01-14 | — | — | US | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | ZHEJIANG ZYLOX MEDICAL DEVICE CO., LTD. (CN) | 2015-02-19 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | CA2 2055/4885CA12 3875/4885CA1 4118/4885 |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | CA2 4564/4885CA12 4522/4885CA1 4654/4885 |
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CA2 1521/4885CA12 453/4885CA1 1162/4885 |
| US-12195510-B2 | Insulin conjugates | IAPP, INSR, IGF1R | CA2 1521/4885CA12 453/4885CA1 1162/4885 |
| US-20150051242-A1 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME | RICTOR, MTOR, RPTOR | CA2 3528/4885CA12 3665/4885CA1 1298/4885 |
| US-20250206798-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CA2 1521/4885CA12 453/4885CA1 1162/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | CA2 1814/4885CA12 3558/4885CA1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.